The Third Annual August M. Watanabe Symposium in Biotechnology Indiana University - Bloomington Saturday, September 29, 2012 - Chemistry 122

2012 Symposium Schedule

The Watanabe Symposium honors the late August "Gus" Watanabe, a renowned physician, researcher and professor who led research and development at Eli Lilly and Company for nearly a decade, and who was a pioneer in the study of the cellular mechanics of the heart. IN 1994, Watanabe assumed the role as President of Lilly Research Laboratories and is responsible for launching eleven new and pivotal pharmaceutical products. IU hosted the 2nd annual Watanabe on October 15, 2011.

Kate Carroll

Associate Professor, Department of Chemistry
The Florida Scripps Research Institute

Kate Carroll completed her undergraduate degree in Biochemistry from Mills College and her PhD in Biochemistry from Stanford. The goal of Dr. Carroll's research is to understand molecular mechanisms that underlie redox-regulation of protein function and how redox systems modulate complex physiological processes in normal and disease states. To achieve these goals, we develop and apply new technologies that cut across the traditional boundaries of chemical and biological sciences.



Tom Kodadek

Professor, Department of Cancer Biology
Faculty, Kellogg School of Science and Technology
The Florida Scripps Research Institute

Tom Kodadek completed his BS in Chemistry from University of Miami and his PhD in Organic Chemistry from Stanford University. The Kodadek Laboratory focuses on understanding and manipulating biological pathways important in various disease states. Our approach relies heavily on chemical methods and a major goal in each of the biological areas of interest is to develop compounds that serve as leads for drug development or can be employed as tools for mechanistic studies. The three areas of biology currently under investigation are: 1) autoimmune diseases and lymphomas, 2) the involvement of the proteasome in transcription and 3) the function of the hormone orexin in narcolepsy, diabetes and other diseases.



Scott McLuckey

John A. Leighty Distinguished Professor
Department of Chemistry, Purdue University

McLuckey did his undergraduate studies at Westminster College and his Ph.D. from Purdue University. After a year of postdoctoral studies in Amsterdam, McLuckey joined the research staff of Oak Ridge National Laboratory, where he remained until 2000 when he moved to Purdue. His research concerns the formation of ionized versions of large biomolecules, mass spectrometry of these ions, and ion-ion reactions. In 1997, the American Society for Mass Spectrometry gave him the first Biemann Medal for his contributions to mass spectrometry. He was named scientist of the year at Oak Ridge in 1999. In 2000, he received the Curt Brunnée Award of the International Mass Spectrometry Society, given annually to a researcher under the age of 45. He received the 2007 Award in Chemical Instrumentation of the American Chemical Society Division of Analytical Chemistry, and the Anachem Award in 2008 from the National Federation of Analytical Chemistry and Spectroscopy.



Peter Schultz

Professor of Chemistry, Scripps Research Institute
Director of the Genomics Institute of the Novartis Research Foundation

Peter G. Schultz graduated (summa cum laude) from Caltech and continued there for his doctoral degree. He then spent a year at the Massachusetts Institute of Technology before moving to the University of California, Berkeley, and the Howard Hughes Medical Institute. Schultz has made a number of major contributions to science including: (1) the discovery of catalytic antibodies, and their use to study fundamental mechanisms of biological catalysis and the evolution of binding and catalytic function; (2) the development of technology that for the first time enables the systematic expansion of the genetic codes of living organisms to include unnatural amino acids beyond the common twenty; and (3) the development and application of combinatorial methods in chemistry and biology including the first generation of combinatorial materials libraries and the isolation of molecules that control stem cell proliferation and fate. Schultz has received numerous awards including the Alan T. Waterman Award, NSF, the ACS Award in Pure Chemistry, the U.C. Berkeley College of Chemistry Teaching Award, the Wolf Prize in Chemistry, the Paul Erhlich and Ludwig Darmstaedter Award, and the ACS Arthur C. Cope Award.



Joanne Stubbe

Novartis Professor of Chemistry & Biology
Massachusetts Institute of Technology

Professor JoAnne Stubbe is an internationally recognized leader in mechanistic enzymology and bioinorganic chemistry. She has held academic appointments at Williams College, Yale University, the University of Wisconsin, and, since 1987, the Massachusetts Institute of Technology. She is currently the Novartis Professor of Chemistry and Biology. In 2009, Professor Stubbe won the National Medal of Science. Professor Stubbe has made seminal contributions to a number of different areas of biochemistry. Work from her laboratory has been central to the elucidation of the catalytic mechanism of ribonucleotide reductases. Her laboratory's ground-breaking mechanistic experiments on the anticancer drug bleomycin have provided essential insights into how this drug causes DNA damage. The Stubbe group has carried out pioneering mechanistic investigations on polyhydroxybutyrate synthase and related enzymes that participate in the biosynthesis of industrially useful bioplastics.





August M. Watanabe

Dr. August M. Watanabe was a renowned physician, researcher, professor, entrepreneur, and venture capitalist. He was the founding Chairman of BioCrossroads, and developed the initial strategic plan that established the organization. Dr. Watanabe was Executive Vice President of Science and Technology and a member of the Board of Directors at Eli Lilly and Company from 1996 to 2003. He joined Lilly in 1990, and became President of Lilly Research Laboratories in 1994. Under his leadership, Lilly launched 11 important new pharmaceutical products. Prior to joining Lilly, Dr. Watanabe was a full-time faculty member of the Department of Medicine at the Indiana University School of Medicine from 1971 to 1990. In 1978, he became the youngest Professor of Medicine at the university, and from 1983 to 1990, he was the Chairman of the Department of Medicine. Dr. Watanabe served as co-founder of Marcadia Biotech, partner in Twilight Venture Partners, and a director of Ambrx, Endocyte, QuatRx, and Kalypsys. He was also a senior advisor to Frazier Healthcare Ventures. He also remained active in the community, serving as a director of the Indiana University Foundation, the Regenstrief Foundation, Christel House International, and the Indianapolis Symphony Orchestra. During his academic and research career, Watanabe co-authored more than 100 scientific publications and book chapters and served on the editorial boards of scholarly journals and as an officer in several national academic organizations, including the American College of Cardiology and the American Heart Association. Dr. Watanabe received his B.S. from Wheaton College and his MD from the Indiana University School of Medicine.